Endothelin (ET) is a vasoactive peptide produced by both endothelial and epithelial cells with documented mitogenic action on mesangial cells. The present studies were designed to test the hypothesis that ET is also produced by human mesangial cells (HMC) 
Introduction
Recent studies demonstrate the presence of mRNA for endothelin as well as production of this vasoactive peptide in cells derived from both ectodermal (epithelial) and endodermal (endothelial) origin (1) (2) (3) . Furthermore, studies in cells derived from mesoderm (glomerular mesangial cells) demonstrate the existence of two different endothelin receptors as well as the ability ofexogenous endothelin to increase mitogenesis ofthese cells (4) (5) (6) (7) . The present studies were designed to test the hypothesis that normal human glomerular mesangial cells, in culture, produce endothelin and that other mitogenic peptides such as arginine vasopressin and insulin potentiate this production. Furthermore, these experiments were designed to assess whether endogenously produced endothelin modulates, in part, the mitogenic effects of arginine vasopressin (AVP)' and insulin on normal human mesangial cells (HMC). AVP was then diluted in RPMI 1640 in the stock Hepes/0.1% BSA solution to the desired concentration on the day of the experiment. PMP Isolation and identification of human mesangial cells. Mesangial cells were isolated from renal cortical tissue obtained following total nephrectomy in patients with carcinoma of the renal pelvis. Kidneys were perfused with and maintained in ice-cold Collin's medium at 4VC for < 12 h. After removal of the medulla from kidney tissue, the glomeruli were isolated from renal cortex via differential sieving as previously described (8, 9) . Outgrowths of mesangial cells were subcultured 3-4 wk later in 75-cm2 flasks containing RPMI 1640 and FCS. Identification of these cells was performed by staining the mesangial cells for specific surface antigens. We used murine MAbs to human vimentin and Factor VIII-related antigen to test for specific surface antigens. In addition, further identification was routinely performed using rabbit IgG directed to vascular smooth muscle myosin and FITCconjugated mouse anti-rabbit IgG. These studies indicated a staining pattern considered indicative of human mesangial cells (8) (9) (10) To further support the findings of these studies, we repeated the above mentioned studies using a MAb against ET-1. A MAb to ET-I was developed in the following manner: pure endothelin was obtained and conjugated to keyhole limpet hemocyanin as previously described (I12-13). The conjugated peptide was mixed in CFA and used for immunization of 5-8-wk-old (BALB/cA/JFl) mice. Immunization, cell fusion (fusion cells are SP/02), cloning by limited dilution, and ascites production were carried out as previously described (I13). The endothelin MAb was found to be specific for ET-I but had a > 50% reactivity with ET-2 and < 30% reactivity with ET-3 as determined by RIA. The antibody detected ET-I at a dilution of 1:100,000 with a sensitivity of I pM/ml. The binding affinity (equilibrium dissociation constant; Kd) for ET-I as determined by RIA at a dilution of 1:100,000 was I nM. The antibody did not cross-react with secretin, vasoactive intestinal peptide, fl-endorphin, somatostatin, calcitonin gene-related peptide, and peptide yy. The antibody is stable for more than a year when stored frozen at -80'C. The diluted antibody is stable at 4VC for a period of 4 wk.
RIA studies of MAb to ET-I were carried out following dilution to an appropriate concentration (1:100,000) with 10 mM phosphate buffer, pH 7.4, containing 0.1% BSA. To construct the standard curve, aliquots (50 ml) ofthe diluted antibody were incubated at 00C for 16 h with 25 pmol of 125I-endothelin (50 ml, 15,000 cpm) in the absence (control) or in the presence of unlabeled endothelin (100 pM to 100 nM) to a final volume of 200 ml ofphosphate buffer. To determine ET in unknown samples, aliquots of the unknown sample (100 ml) were mixed with 50 ml ofthe antibody and 50 ml ofthe radiolabeled ET and incubated as above. To remove the unbound radiolabeled ET, samples were treated with dextran-coated charcoal suspension (0.5% acid washed activated charcoal Norit A, 0.05% dextran 70,000 prepared in 50 mM Tris buffer, pH 7.4, centrifuged, and resuspended in 10 mM phosphate buffer). Aliquots of the dextran-coated charcoal were then added to each test tube and incubated at 4°C for 20 min with intermittent vortexing (13). The suspension was then centrifuged at 4°C for 15 min and an aliquot ofthe supernatant was removed and counted. The radioactivity is corrected for sample volume and isotope decay.
To assess the effect ofa MAb against ET-l and the subsequent effect on AVP and insulin-induced mitogenesis, we prepared cells for proliferation studies as previously mentioned and used 10 ml of a dilution of 1:50,000 of a MAb to ET-I in 96-well plates under both quiescent (0.5% FCS) and proliferative (10% FCS) conditions in the presence and absence of AVP (106 M) as well as insulin. Studies were performed at 48 h in a manner similar to that previously described. All studies were performed in triplicate. DNA replication studies of HMC, [3H]-thymidine incorporation into DNA was used. Mesangial cells were detached from plates with trypsin/EDTA and [3H]thymidinecontaining DNA was collected on glass fibrostrips using an automated cell harvester (Pharmacia LKB, Piscataway, NJ).
[3H]Thymidine content was determined using a BetaMax liquid scintillation counter at 5 min per sample. All conditions were performed in triplicate. Cell counts were routinely conducted in all conditions to ascertain HMC replication, microscopically. The number of viable cells was determined by first washing the cells with DPBS three times, then incubating them in 50 ul of trypsin for 30 min at 37°C, which results in complete detachment of HMC. The detached cells were resuspended with equal volumes of0.4% trypan blue and growth medium and transferred to a counting chamber where the number of viable cells was counted using inverted phase contrast microscopy.
Determination of mesangial cell endothelin production. ET was measured in conditioned medium from both quiescent (0.5% FCS) and proliferative (1 0I FCS) conditions in the presence and absence ofinsulin as well as under various concentrations of arginine vasopressin. Endothelin assays were performed immediately after each group of experiments.
HMC were plated in 75-cm2 flasks and allowed to achieve confluency. Cells were then washed three times with DPBS, and basal medium containing 0.5% FCS was added. After 48 h the medium was aspirated from each flask and all cells were washed with DPBS. Then flasks received either basal medium (0.5% FCS) or growth medium (10% FCS); only halfof each set offlasks contained insulin S g/ml. ET was then measured in conditioned medium at 24, 48, and 72 h. This procedure was repeated in a separate set ofexperiments, each in triplicate, where either 10-0 M, 1O-8 M, or 10-6 M AVP was added to each flask in the presence or absence of insulin. Similar determinations of ET were carried out at 24, 48, and 72 h in conditioned medium ofcells that were used in studies using ETAS that did not receive the antiserum. All endothelin values in the text are corrected for ET present in the accompanying media. ET was measured using a specific and sensitive RIA which has been previously described (14) . The level ofdetect-ability of this assay was 0.5 pg/mi with a range of 0.5-400 pg/ml. The interassay and intraassay variationswere 7.5±1.2 and 2.1±1.5%, respectively.
In addition, experiments to determine the presence ofendothelin in FCS were performed examining various concentrations of FCS (0.5, 5, 10, and 20%). ET was also measured in RPMI 1640 alone as control.
Statistics. Data were analyzed using both analysis of variance with subgroup analysis and Student's t test for paired and unpaired groups, where applicable. All data are expressed as mean±SEM, unless otherwise noted.
Results
Endothelin production. ET levels were measured in various concentrations of FCS and compared with medium alone (Fig.  1) . Furthermore, ET was present at higher concentrations in conditioned medium after 48 h incubation with mesangial cells compared with FCS during the same latency period (Fig. 1) . Thus, even when corrected for concentrations of ET in FCS, quiescent HMC produce on average 2.2±0.4 pg/ml of ET at 48 h in the presence of insulin. Moreover, ET production appears to plateau at 48 h, a trend that correlates with cellular proliferation (Fig. 2 ).
Insulin at a concentration of 5 gg/ml did not significantly change ET concentration in quiescent cells (Fig. 2) . However, when insulin was added to either proliferative or quiescent cells in the presence of varying concentrations of AVP, there was a significant increase in ET concentrations above that seen with AVP alone (Figs. 2-4) .
AVP alone in ascending concentrations increased ET production on proliferative as well as quiescent mesangial cells in a dose-dependent fashion, an effect that correlated with its effect on mitogenesis and cell counts (Figs. 2-4 Addition of a selective VI receptor antagonist, PMP, 1 h before addition of AVP markedly attenuated the rise in ET concentration in conditioned medium as well as mitogenesis ( Fig. 5 and Table I ). This inhibitory effect of PMP was overcome by simultaneous addition of ET (10-9 M) to PMP (Table  I) . Furthermore, while insulin significantly increased both ET concentration in conditioned medium and mitogenic activity ofAVP, it failed to increase mitogenesis ofET concentration in conditioned medium in the presence of PMP (Fig. 5) .
[3H]Thymidine incorporation and mitogenesis. AVP increased mesangial cell proliferation in a dose-dependent fashion ( Figs. 3 and 4 (15) . We further support the finding that insulin augments for the mitogenic effect of ET on these cells (7) . Furthermore, the dose and time course over which this occurred is similar to previous reports (15) . In addition, our data confirm previous reports that selective inhibition of V1 receptors attenuates the mitogenic response of vasopressin in the presence and absence of insulin (15, 16 ). by insulin (Figs. 2, 5-7 ). However, this stimulatory effect of insulin on mitogenesis was markedly attenuated in the presence of either ETAS, a MAb against ET-1, or the VI receptor antagonist, PMP (Table I and Figs. 3-7) . Cell counts correlated with this blunted effect in cell mitogenesis (Figs. 3-7) , with no significant differences in cell viability between the different conditions tested (data not shown). Furthermore, the inhibitory effect of ETAS, AbET, or PMP could not be overcome by addition of insulin to AVP (10-6 M) (Figs. 3-7) . However, addition ofendothelin (1 0-9 M) in the presence of PMP and insulin resulted in a significant increase in mitogenesis, an effect that approximated vasopressin alone (Table I ). This effect on mitogenesis was not seen in the absence of insulin (7.3+0. The interrelationship between AVP and cellular production of ET, however, has not been previously described in HMC. We present evidence that AVP increases ET production by HMC. We also demonstrate that binding of ET, produced by HMC, with either ETAS or a MAb directed against ET-1 significantly attenuates the mitogenic effects of AVP. Further evidence to support the notion that AVP modulates its mitogenic effect through stimulation of ET is supported by the observation that addition of ET-1 to these cells, pretreated with a selective vasopressin-1 receptor antagonist, results in increased cell growth and mitogenic activity.
One possible explanation for the observation that ET concentration increases after administration of AVP is that ET concentration in the media is a reflection ofincreased cell number. However, when ET concentration is evaluated per cell, there is clearly a greater increase in the cells treated with AVP compared with vehicle, thus supporting the notion that ET concentration is truly elevated after AVP administration. Second, a comparison of ET concentration per cell in both quiescent (0.5% FCS) and proliferative (20% FCS) culture milieus in the presence of insulin and absence of AVP does not demonstrate an increased ET concentration per cell. Taken together, these data support the concept that ET production is increased by AVP and that AVP stimulates mitogenesis of HMC, in part by stimulating endogenous ET production. The sole mitogenic effect of AVP on mesangial cells does not totally depend on its stimulation ofET production by these cells. We demonstrate that addition of ET to cells previously treated with both AVP and a vasopressin receptor antagonist only approximated (-72%) the mitogenic effect of AVP alone. A number of possible explanations may account for this observation. First, mesangial cells are known to contain mRNA of various growth factors. These include: plateletderived growth factor, IGF-I, transformation growth factor A, IL-1, etc. These factors have been shown to modulate the mitogenic response of many growth factors and all but transformation growth factor (3 increase cellular proliferation (17) (18) (19) . It is possible that some or all of these growth factors participate in the mitogenic action ofAVP, thus accounting for only a partial mitogenic response when ET was added to the culture milieu, although no data supporting this contention are currently available. Second, both AVP and ET may stimulate growth through a calcium-dependent protein kinase C mechanism (20) (21) . However, the relative stimulatory effect of ET on cytosolic free calcium is much less than that of AVP (21) . This disparity of response may also contribute to the discrepancy in the mitogenic effect between these two peptides.
Insulin is known to be a potent mitogen in certain tumor cell lines through its binding to a specific tyrosine kinase receptor and through activation ofprotein kinase (22, 23) . The mitogenic effects of insulin on mesangial cells are known to result, in part, from stimulation of IGF-I receptors rather than insulin receptors on these cells (24) . In addition, stimulation of IGF-I receptors has been shown to potentiate the effects of other vasoactive hormones (25) . Previous studies also show that insu- lin, at a dose used in our study, potentiates the mitogenic effects of various vasoactive peptides on mesangial cells, although insulin by itself is a relatively weak mitogen in comparison to these peptides (15, (26) (27) . Furthermore, the action of various mitogenic peptides such as AVP or angiotensin II on mesangial cells is markedly blunted or absent ifinsulin is not present in the culture milieu (15, 28, 29) . Our data support these findings in that insulin potentiates the mitogenic effect ofAVP in HMC. Furthermore, insulin, in the absence of AVP, had no significant effect on endogenous ET production, an effect that was markedly altered in the presence of AVP. Addition of insulin to the culture milieu also potentiated the antimitogenic effects ofETAS as well as the MAb against ET-1. This effect ofinsulin, however, still needs to be fully elucidated.
We conclude that the vasoactive peptide ET modulates, in part, the mitogenic response of AVP on HMC. We further conclude that insulin augments this interaction. Further experiments that explore the interactions between these two peptides may help elucidate the behavior of mesangial cells under other mitogenic stimuli such as angiotensin II, platelet-derived growth factor, and the like. 
